Skip to main content

Table 1 Clinicopathological parameters of patients with CD68, CD163, VEGF-A, or VEGF-C expression in patients with NSCLC

From: Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients

Category (n = 349) CD68 CD163 CD163 + /CD68 + (M2 ratio) VEGF-A VEGF-C
High n (%) Low n (%) p High n (%) Low n (%) p High n (%) Low n (%) p High n (%) Low n (%) p High n (%) Low n (%) p
Total 174 (49.9) 175 (50.1)   174 (49.9) 175 (50.1)   174 (49.9) 175 (50.1)   174 (49.9) 175 (50.1)   175 (50.1) 174 (49.9)  
Age    0.816    0.183    0.816    0.418    0.583
  < 60 36 (20.7) 39 (22.3)   43 (24.7) 32 (18.3)   36 (20.7) 39 (22.3)   41 (23.6) 34 (19.4)   35 (20.0) 40 (23.0)  
  ≥ 60 138 (79.3) 136 (77.7)   131 (75.3) 143 (81.7)   138 (79.3) 136 (77.7)   133 (76.4) 141 (80.6)   140 (80.0) 134 (77.0)  
Sex    1.000    0.587    0.017    0.314    0.001
 Male 120 (69.0) 121 (69.1)   123 (70.7) 118 (67.4)   131 (75.3) 110 (62.9)   125 (71.8) 116 (66.3)   136 (77.7) 105 (60.3)  
 Female 54 (31.0) 54 (30.9)   51 (29.3) 57 (32.6)   43 (24.7) 65 (37.1)   49 (28.2) 59 (33.7)   39 (22.3) 69 (39.7)  
Tumor type    0.231    0.027    0.585    0.015     < 0.001
 SqCC 74 (42.5) 61 (34.9)   79 (45.4) 56 (32.0)   72 (41.4) 63 (36.0)   80 (46.0) 55 (31.4)   89 (50.9) 46 (26.4)  
 AD 99 (56.9) 111 (63.4)   94 (54.0) 116 (66.3)   100 (57.5) 110 (62.9)   93 (53.4) 117 (66.9)   86 (49.1) 124 (71.3)  
 ADSq 1(0.6) 3 (1.7)   1 (0.6) 3 (1.7)   2 (1.1) 2 (1.1)   1 (0.6) 3 (1.7)   0 4 (2.3)  
Grade    0.030    0.360    0.446    0.446    0.001
 Well 51 (29.3) 74 (42.3)   56 (32.2) 69 (39.4)   68 (39.1) 57 (32.6)   58 (33.3) 67 (38.3)   47 (26.9) 78 (44.8)  
 Moderate 84 (48.3) 74 (42.3)   84 (48.3) 74 (42.3)   75 (43.1) 83 (47.4)   79 (45.4) 79 (45.1)   95 (54.2) 63 (36.2)  
 Poor 39 (22.4) 27 (15.4)   34 (19.5) 32 (18.3)   31 (17.8) 35 (20.0)   37 (21.3) 29 (16.6)   33 (18.9) 33 (19.0)  
  pT stage    0.417    1.000    1.000    0.891    0.891
 T1-2 148 (85.1) 155 (88.6)   151 (86.8) 152 (86.9)   151 (86.8) 152 (86.9)   152 (87.4) 151 (86.3)   151 (86.3) 152 (87.4)  
 T3-4 26 (14.9) 20 (11.4)   23 (13.2) 23 (13.1)   23 (13.2) 23 (13.1)   22 (12.6) 24 (13.7)   24 (13.7) 22 (12.6)  
pN stage    0.580    0.750    0.533    0.580    0.208
 0 126 (72.4) 121 (69.1)   125 (71.8) 122 (69.7)   120 (69.0) 127 (72.6)   126 (72.4) 121 (69.1)   118 (67.4) 129 (74.1)  
 1–3 48 (27.6) 54 (30.9)   49 (28.2) 53 (30.3)   54 (31.0) 48 (27.4)   48 (27.6) 54 (30.9)   57 (32.6) 45 (25.9)  
Stage    0.659    0.914    0.125    0.407    0.106
 I 110 (63.2) 108 (61.7)   111 (63.8) 107 (61.1)   108 (62.1) 110 (62.9)   112 (64.4) 106 (60.6)   100 (57.1) 118 (67.8)  
 II 34 (19.5) 38 (21.7)   36 (20.7) 36 (20.6)   34 (19.5) 38 (21.7)   38 (21.8) 34 (19.4)   45 (25.7) 27 (15.6)  
 III 25 (14.4) 27 (15.4)   24 (13.8) 28 (16.0)   31 (17.8) 21 (12.0)   22 (12.6) 30 (17.1)   26 (14.9) 26 (14.9)  
 IV 5 (2.9) 2 (1.2)   3 (1.7) 4 (2.3)   1 (0.6) 6 (3.4)   2 (1.2) 5 (2.9)   4 (2.3) 3 (1.7)  
  1. NSCLC non-small cell lung cancer, AD adenocarcinoma, SqCC squamous cell carcinoma, ADSq adenosquamous carcinoma, VEGF vascular endothelial growth factor